In a report released today, Sean Kim PhD from JonesTrading reiterated a Buy rating on Ocuphire Pharma (OCUP – Research Report), with a price target of $18.00. The company’s shares closed today at $4.51.
According to TipRanks, Kim PhD is a 3-star analyst with an average return of 3.6% and a 37.14% success rate. Kim PhD covers the Healthcare sector, focusing on stocks such as Ocuphire Pharma, Trevi Therapeutics, and Phathom Pharmaceuticals.
Currently, the analyst consensus on Ocuphire Pharma is a Moderate Buy with an average price target of $19.00, implying a 321.29% upside from current levels. In a report released on March 31, H.C. Wainwright also reiterated a Buy rating on the stock with a $20.00 price target.
See the top stocks recommended by analysts >>
The company has a one-year high of $3.92 and a one-year low of $1.78. Currently, Ocuphire Pharma has an average volume of 109.7K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Rexahn Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of oncology therapeutics. Its drug candidates include the following: RX-31171 for pancreatic, bladder, colon, and lung cancer; and RX-5902 for metastatic triple negative breast cancer. The company was founded by Chang Ho Ahn on March 19, 2001 and is headquartered in Rockville, MD.
Read More on OCUP:
- Ocuphire Pharma Announces Financial Results for Fourth Quarter and Year Ended 2022 and Provides Corporate Update
- Ocuphire Pharma reports FY22 EPS $1.58, consensus 6c
- Ocuphire Pharma announces APX3330 Phase 2 data presentations at retina meetings
- Ocuphire Pharma announces FDA acceptance of NDA for Nyxol
